The news came out today. Not only was it approved but it was fast-tracked. The drug is for breast cancer, but does not treat all patients with breast cancer. It seems to only work on a certain type of cancer. It also does not have any impact on the tumor., but it does attack the cancer in the tumor.
In short, the drug seems to only be effective in certain women with breast cancer, and only extends the survival time by a small number. Yet it was fast-tracked and FDA approved today.
I just saw a segment on FOX news about Kadcyla. It is being hearlded as a "AMAZING BREAKTHORUGH" in cancer treatment with tumor shrinkage with no other tissue damage.
Per Fox news it was rapidly approved by the FDA after clinical tests showed it helped 20% of breast cancer patients survive an additional 3.5 months. To repeat 20% with an additional 3.5 months survival.
That sort of shed a different light on the India trial numbers to some saying 33% living additional 6 months longer than expected is a low number.
Media makes it sound great but it is still "old tech" chemo poison. Facny delivery system is all. We are as different from it as modern medicine to medieval medicine.
From my limited understanding it looks like it as exactly what you described. A targeted delivery system delivering chemo only targeting cancer cells. Old school but still a good improvement from currently approved options.